Edesa Biotech Inc.

We're pleased to announce a strategic license agreement with Kyorin Pharmaceutical to develop and commercialize #paridiprubart in #Japan for #ARDS. Kyorin brings respiratory medicine expertise and a strong presence in Japan. $EDSA globenewswire.com/news-relea…

Edesa Biotech announces FDA IND clearance for Phase 2 #vitiligo study. Recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter. globenewswire.com/news-relea…

Edesa Biotech today reported #financialresults for fiscal Q3 2026 $EDSA #vitiligo #ARDS globenewswire.com/news-relea…

Exploratory data on #paridiprubart in patients with acute kidney injury (#AKI) and respiratory distress to be presented today at #ERA26. globenewswire.com/news-relea…

Edesa plans to present new #paridiprubart data in patients with acute #kidney injury and respiratory distress at the annual #ERA26 Congress, to be held June 3-6, 2026 in Scotland #AKI #ARDS $EDSA globenewswire.com/news-relea….

Edesa Biotech today reported #financialresults for fiscal 2Q 2026 $EDSA #vitiligo #ARDS globenewswire.com/news-relea…

Edesa is pleased to announce that our CEO, Dr. Par Nijhawan, has been selected to deliver the inaugural presentation at the #RIS2026 Oral Showcase at #ATS2026 #ARDS $EDSA globenewswire.com/news-relea…

Edesa Biotech advances #vitiligo clinical development program, selects JSS Medical Research as CRO for planned Phase 2 study. globenewswire.com/news-relea… $EDSA #dermatology #AAD2026

Additional clinical data from Edesa’s #Phase3 study affirmed statistically significant mortality reductions in the full population of 278 patients. Exploratory analysis also demonstrated reduced mortality in #AKI, #sepsis and #pneumonia. globenewswire.com/news-relea…

Edesa Biotech today reported #financialresults for fiscal 1Q 2026 $EDSA #vitiligo #ARDS globenewswire.com/news-relea…

Edesa Biotech today reported #financialresults for fiscal year 2025 $EDSA globenewswire.com/news-relea…

Edesa’s #Phase3 study of paridiprubart in patients with #ARDS met its primary and secondary endpoints, showing demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. $EDSA #biotech #drugdevelopment nasdaq.com/press-release/ede…

Edesa to participate in the @HCWCO 27th Annual Global Investment Conference next week in New York #HCWConference #vitiligo #ARDS $EDSA

Edesa Biotech today reported #financialresults for fiscal 3Q 2025 $EDSA globenewswire.com/news-relea…

Edesa Biotech is a proud sponsor and supporter of World #Vitiligo Day and this year’s theme “Innovation for Every Skin” #WVD2025 #biotechnology #CXCL10 $EDSA worldvitiligoday.ca/

Edesa Biotech today reported #financialresults for fiscal 2Q 2025 $EDSA globenewswire.com/news-relea…

Edesa to join the annual Bloom Burton Healthcare Investor #Conference next week. $EDSA #vitiligo #BBHIC2025 globenewswire.com/news-relea…

Edesa is pleased to announce that Peter Weiler will assume the role of CFO on May 1. Peter is a veteran of the #pharma and #biotech sectors, with extensive experience in finance and corporate strategy. globenewswire.com/news-relea…

Congratulations to the Global #Vitiligo Foundation for hosting a great scientific symposium this week at #AAD2025. Edesa is proud to provide support for advancing research, education and collaboration within the vitiligo community.

Edesa Biotech today reported #financialresultsfor fiscal 1Q 2025 #vitiligo #ACD #ARDS #fibrosis $EDSA globenewswire.com/news-relea…